EyeGate Pharmaceuticals Licensing Deal Review and Breakdown

February 22, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap securities is providing an in-depth review of EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) licensing deal with Valeant and much more in our full deal breakdown report today. EyeGate announced an exclusive licensing agreement with Valeant Pharmaceuticals on February 21, 2017. Under the terms of the licensing agreement, EyeGate will receive a $4.0 million upfront payment and is eligible to receive potential development-based milestone payments and royalties on Valeant’s net sales of the product totaling up to approximately $99.0 million.

By extending the relationship with Valeant, EyeGate has retained a reputable partner who has the capabilities to bring the product to market. With this agreement, EyeGate will continue to be responsible for development costs, but with more financial resources, the company can continue the development of the unique EGP-437 product.

Get the additional details and milestones here in the FULL REPORT

(Copy and paste to your browser may be required to view this report- http://bit.ly/2l5KVwb-EYEG-Report)

EyeGate also recently acquired Jade Therapeutics Inc., a privately-held company that develops locally administered, polymer-based products designed to treat poorly-served ophthalmic indications.

EyeGate’s acquisition was synergistic in more ways than one, find out more here READ MORE

(Copy and paste to your browser may be required to view this report- http://bit.ly/2l5KVwb-EYEG-Report)


Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Brandon GEE, (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



SOURCE: Traders News Source